GlassScriptPhysician profile
Chaim S Levine
NPI 1962442863
$1,831.32
in general payments reported to CMS, 2019-2025
21 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $249 · 2021: $46.72 · 2022: $358 · 2023: $253 · 2024: $472 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $319.36 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $249.04 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $187.11 | 2020-2024 | |
| Edwards Lifesciences Corporation | $150.00 | 2024 | |
| Merck Sharp & Dohme LLC | $147.71 | 2024-2025 | Verquvo |
| Pfizer INC. | $141.44 | 2019-2024 | |
| Medtronic, INC. | $118.77 | 2022 | |
| Abbott Laboratories | $92.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $61.14 | 2022-2025 | Camzyos |
| Amarin Pharma, INC. | $58.72 | 2019-2020 | |
| Boston Scientific Corporation | $54.56 | 2023-2024 | Watchman Flx, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $50.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.73 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.76 | 2019-2020 | |
| Cook Medical LLC | $23.02 | 2025 | Zenith Alpha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.75 | 2020 | |
| Glaxosmithkline, LLC. | $17.56 | 2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.22 | 2024 | Arcalyst |
| Novo Nordisk INC | $15.32 | 2025 | Ozempic, Rybelsus |
| Medicomp INC | $13.66 | 2025 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.